newsfilter
← Latest News
GlobeNewswire·

SEMA4D Blockade Reshapes the Tumor Immune Environment in Neoadjuvant Melanoma Study

ROCHESTER, N.Y., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc. a clinical-stage biotechnology company pioneering a differentiated approach to treating Cancer and Alzheimer’s disease (AD) through the inhibition of